Our ultimate goal is to create and sell valuable diagnostic products to help improve lives through reducing healthcare costs and improving patient outcomes.
Our mission is to provide innovative and non-invasive cancer monitoring tools for veterinarian and human oncologists to effectively diagnose and monitor cancer treatment for all cancer patients.
Angio360 is developing diagnostic products for two different markets; the veterinary oncology market and human oncology market. Currently, as cancer treatments for companion animals becomes more prevalent, there is a growing demand for non-invasive oncology diagnostic tools in the veterinary market. For the human oncology market, there is a large unmet need for simple diagnostic methods for assessing cancer treatment efficacy and tumor recurrence in neurological-based cancers, such as gliomas and other types of cancers in which there is currently a lack of reliable blood tumor biomarkers.